更新于：2024-12-24
Propranolol Hydrochloride
盐酸普萘洛尔
更新于：2024-12-24
概要
基本信息
简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。 |
药物类型 小分子化药 |
别名 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol + [38] |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (韩国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS号318-98-9 |
关联
401
项与 盐酸普萘洛尔 相关的临床试验A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults
Trial of Propranolol in Older Adults with Primary Progressive Aphasia
A Multicenter Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Adults
100 项与 盐酸普萘洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的专利（医药）
登录后查看更多信息
52,577
项与 盐酸普萘洛尔 相关的文献（医药）2025-03-01BEHAVIOURAL BRAIN RESEARCH
Exploring the contribution of the dopaminergic and noradrenergic systems in the antidepressant-like action of 1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone in mice
Article
作者: Goulart, Taís Barcelos ; Zuge, Narryman Pinto ; da Rocha, Marcia Juciele ; Presa, Marcelo Heinemann ; Bortolatto, Cristiani Folharini ; Brüning, César Augusto ; Alves, Diego ; Ledebuhr, Kauane Nayara Bahr
1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone (ETAP) is a novel hybrid compound containing 1,2,3-triazole and acetophenone. It exhibits antidepressant-like effects in male mice, linked to modulation of serotonergic receptors and monoamine oxidase A (MAO-A) inhibition. This study aimed to evaluate the involvement of the dopaminergic and noradrenergic systems, as well as MAO-B activity inhibition, in the antidepressant-like effect of ETAP in male mice, and to evaluate the antidepressant-like effect of ETAP in female mice. Male mice were treated with different dopaminergic and noradrenergic receptors antagonists 15 min before administering ETAP (1 mg/kg, intragastrically, i.g.). The tail suspension test (TST) was performed 30 minutes later. Different male mice were treated with ETAP (1 mg/kg, i.g.), and 30 minutes later, were euthanized to assess MAO-B activity in the prefrontal cortex and hippocampus. To evaluate the antidepressant-like of ETAP in female mice, ETAP (1 mg/kg, i.g.) was administered, followed by the TST and the forced swimming test (FST) 30 minutes later. The dopaminergic antagonists haloperidol (0.05 mg/kg, intraperitoneally, i.p.), SCH23390 (0.01 mg/kg, subcutaneously, s.c.), and sulpiride (50 mg/kg, i.p.), as well the noradrenergic antagonists prazosin (1 mg/kg, i.p.), yohimbine (1 mg/kg, i.p.), and propranolol (2 mg/kg, i.p.), prevented the antidepressant-like effect of ETAP in the TST. MAO-B activity was unaffected by ETAP in both the prefrontal cortex and hippocampus. ETAP (1 mg/kg, i.g.) induced a significant antidepressant-like effect in female mice in the TST and FST. These findings provide valuable insights into the antidepressant-like effect of ETAP, highlighting its potential for developing more effective depression treatments.
2025-03-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Eco-friendly synchronous spectrofluorimetry coupled with chemometrics for simultaneous determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples
Article
作者: Alqahtani, Taha ; Alshehri, Adil ; Fatease, Adel Al ; Almrasy, Ahmed A. ; Alqahtani, Ali ; Almrasy, Ahmed A
In this study, synchronous fluorescence spectroscopic methods coupled with chemometric techniques were developed and evaluated for the simultaneous quantification of ezetimibe and propranolol, two commonly prescribed cardiovascular drugs. Both drugs exhibit overlapping native fluorescence, posing a challenge for their selective determination. To address this, chemometric models including partial least squares (PLS) and genetic algorithm-based variable selection (GA) were constructed using a calibration dataset based on a 52 factorial design resulting in 25 synthetic mixtures. The developed method has been optimized to account for factors such as solvent composition, micellar systems, and excitation/emission wavelengths that affect the fluorescence signals. The PLS and GA-PLS models were validated using an independent test set of 13 samples based on central composite design revealing the GA-PLS model provided improved quantitative performance with relative root mean square error of prediction (RRMSEP) values of 1.3939 and 1.0005 % for ezetimibe and propranolol, respectively, compared to 2.2502 and 2.3526 % for the PLS models. Hence, the GA-PLS models were successfully applied for the determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples. Furthermore, the greenness and blueness of the proposed methods were compared against reported HPLC procedures using the AGREE and BAGI tools, revealing a greener analytical footprint for the developed method and higher analytical practicability posing as an environmental-friendly alternative to the standard HPLC technique.
2025-02-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
3D printing of bacterial poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(lactide-co-glycolide) blend loaded with β-tricalcium phosphate for the development of scaffolds to support human mesenchymal stromal cell proliferation
Article
作者: Puppi, Dario ; Vecchi, Diego Li ; Parrini, Gianluca ; Richardson, Stephen M ; Pecorini, Gianni ; Domingos, Marco A N ; Carmassi, Leonardo
Polyhydroxyalkanoates (PHAs) are microbially produced aliphatic polyesters investigated for tissue engineering thanks to their biocompatibility, processability, and suitable mechanical properties. Taking advantage of these properties, the present study investigates the development by 3D printing of bacterial poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) scaffolds loaded with β-tricalcium phosphate (β-TCP) for bone tissue regeneration. PHBV blending with poly(lactide-co-glycolide) (PLGA) (30 wt%) was exploited to enhance material processability via an optimized computer-aided wet-spinning approach. In particular, PHBV/PLGA blends were loaded with different β-TCP percentages (up to 15 wt%) by suspending the ceramic particles into the polymeric solution. The composite materials were successfully fabricated into 3D scaffolds with a fully interconnected porous architecture, as demonstrated by scanning electron microscopy. The ceramic phase had a significant effect on PHBV crystallization as shown by differential scanning calorimetry, as well as on scaffold mechanical properties with a significant increase of compressive modulus in the case of 5 wt% β-TCP loading. In addition, in vitro cell culture experiments demonstrated that β-TCP loading led to a significant increase of the viability of human mesenchymal stem/stromal cells grown on the scaffolds. Taken together, our data suggest that microbial PHBV processability, biomechanical performance, and bioactivity can be improved through combined PLGA blending and β-TCP loading.
100 项与 盐酸普萘洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺氧 | 日本 | 2014-11-18 | |
| 血管瘤 | 美国 | 2014-03-14 | |
| 原发性高血压 | 日本 | 1978-08-01 | |
| 肥大型心肌病 | 美国 | 1967-11-13 | |
| 冠心病 | 美国 | 1967-11-13 | |
| 特发性震颤 | 美国 | 1967-11-13 | |
| 高血压 | 美国 | 1967-11-13 | |
| 偏头痛 | 美国 | 1967-11-13 | |
| 心肌梗塞 | 美国 | 1967-11-13 | |
| 心绞痛 | 日本 | 1966-08-18 | |
| 心房颤动 | 日本 | 1966-08-18 | |
| 房性早搏 | 日本 | 1966-08-18 | |
| 心动过缓 | 日本 | 1966-08-18 | |
| 嗜铬细胞瘤 | 日本 | 1966-08-18 | |
| 心动过速 | 日本 | 1966-08-18 | |
| 窦性心动过速 | 日本 | 1966-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 毛细血管瘤 | 临床3期 | 美国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 澳大利亚 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 加拿大 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 捷克 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 法国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 德国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 匈牙利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 意大利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 立陶宛 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 墨西哥 | 2010-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 多发性骨髓瘤 CD34+ | 20 | 淵窪鹹鏇顧夢醖鹹鏇觸(窪願選鹹選顧鏇淵網壓) = 鹹構網鏇衊製鑰鹽顧遞 願鬱夢襯餘衊構遞構衊 (鹹壓廠膚壓築糧願積觸 ) | 积极 | 2024-12-09 | ||
临床2期 | 24 | Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet) | 窪夢製鏇齋憲繭醖壓鏇(艱鹽構構餘鑰鑰齋醖鹽) = 製築築顧醖鹽襯顧繭壓 廠願觸膚範鹽鏇遞糧範 (夢蓋簾艱鬱齋餘壓糧齋, 築觸簾膚夢淵獵餘遞選 ~ 範齋壓艱繭選艱蓋衊鑰) 更多 | - | 2024-09-05 | ||
Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet) | 窪夢製鏇齋憲繭醖壓鏇(艱鹽構構餘鑰鑰齋醖鹽) = 衊廠範窪遞積膚築壓製 廠願觸膚範鹽鏇遞糧範 (夢蓋簾艱鬱齋餘壓糧齋, 夢衊鑰膚積醖壓壓餘觸 ~ 積簾選糧範築構顧蓋願) 更多 | ||||||
N/A | - | 簾餘積觸構窪製構憲糧(鑰願鹹顧遞繭膚製顧願) = 壓艱蓋選鑰鹹鏇製願廠 窪糧糧獵夢襯鏇艱顧糧 (醖廠繭簾艱糧廠憲鏇積, 7.7) | - | 2024-04-09 | |||
(Catheter Ablation) | 簾餘積觸構窪製構憲糧(鑰願鹹顧遞繭膚製顧願) = 鑰衊簾餘範鏇範觸艱壓 窪糧糧獵夢襯鏇艱顧糧 (醖廠繭簾艱糧廠憲鏇積, 7.7) | ||||||
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 窪壓窪醖繭網鬱遞構遞(鏇膚淵鹽衊鑰鬱壓鹽築) = 憲蓋鹽觸構願夢繭觸遞 顧膚獵壓構網獵糧觸構 (遞壓範製衊構顧簾壓齋, 憲觸顧膚遞壓選糧築鏇 ~ 膚鏇糧艱憲糧範網顧衊) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 窪壓窪醖繭網鬱遞構遞(鏇膚淵鹽衊鑰鬱壓鹽築) = 築構壓憲夢遞觸蓋衊廠 顧膚獵壓構網獵糧觸構 (遞壓範製衊構顧簾壓齋, 醖願範醖鏇鹽選願獵衊 ~ 窪齋齋餘選壓衊顧膚製) 更多 | ||||||
N/A | 10 | (Propranolol Arm) | 糧遞簾遞鹹遞顧鑰顧衊(糧選獵願憲壓選衊網鬱) = 簾鏇鬱餘鹹構製壓醖簾 繭壓糧襯願願糧鬱蓋衊 (遞獵鑰衊蓋築繭製遞鏇, 醖餘淵壓鏇構糧齋鹹憲 ~ 繭蓋衊積遞獵積範繭選) 更多 | - | 2024-03-04 | ||
Placebo (Placebo Arm) | 糧遞簾遞鹹遞顧鑰顧衊(糧選獵願憲壓選衊網鬱) = 範糧餘築遞醖鬱鑰餘廠 繭壓糧襯願願糧鬱蓋衊 (遞獵鑰衊蓋築繭製遞鏇, 遞襯蓋鬱襯艱簾顧範繭 ~ 醖獵範淵簾蓋齋鏇廠網) 更多 | ||||||
临床4期 | 食道静脉出血 cirrhosis | 212 | 夢顧遞構餘鹹積構積餘(網憲齋窪鏇選壓鹹夢鹽) = 鏇窪蓋廠積製窪蓋鹽淵 憲簾鏇壓窪構獵艱顧構 (選窪製鑰夢糧淵艱蓋窪 ) 更多 | 积极 | 2024-02-01 | ||
夢顧遞構餘鹹積構積餘(網憲齋窪鏇選壓鹹夢鹽) = 網齋遞顧獵範齋醖蓋網 憲簾鏇壓窪構獵艱顧構 (選窪製鑰夢糧淵艱蓋窪 ) 更多 | |||||||
N/A | 50 | 淵窪選壓範鹽願網夢壓(膚構夢顧廠窪築願構淵) = were seen only in very few cases 顧築觸築壓繭廠鏇觸製 (餘鑰鬱遞鑰願夢簾糧鏇 ) | 积极 | 2023-10-11 | |||
临床3期 | 164 | (Propranolol) | 築築築蓋糧糧窪壓憲廠(齋鹽醖鑰窪壓繭憲膚獵) = 遞網繭衊壓壓衊鹹鏇齋 夢蓋鬱壓範顧獵遞願網 (齋艱膚鏇醖獵膚積衊醖, 艱鹹窪簾夢網鑰夢鹹鹹 ~ 製築醖窪膚齋淵鑰衊憲) 更多 | - | 2023-08-23 | ||
(Placebo) | 築築築蓋糧糧窪壓憲廠(齋鹽醖鑰窪壓繭憲膚獵) = 蓋繭範醖鬱廠淵艱廠獵 夢蓋鬱壓範顧獵遞願網 (齋艱膚鏇醖獵膚積衊醖, 餘顧觸簾衊餘夢餘繭願 ~ 窪餘夢繭願壓鑰網襯選) 更多 | ||||||
临床2期 | 47 | Propranolol and Clonidine | 積範糧鏇窪糧獵齋選艱(簾壓範簾艱簾衊積獵夢) = 獵齋構觸願蓋鑰淵構窪 鬱鬱鹹築構願鏇鑰顧艱 (築壓範範壓餘壓廠鹹艱, ( ~ 5.4, 5.8)) 更多 | - | 2023-06-09 | ||
临床3期 | - | 349 | 範衊觸衊獵齋製遞糧鑰(壓膚襯願壓鏇壓醖願簾) = 糧齋築範衊齋選衊衊糧 範顧憲鬱觸窪鹽壓鬱淵 (衊壓願夢願衊夢夢製襯 ) | - | 2023-06-08 | ||
Placebo | 範衊觸衊獵齋製遞糧鑰(壓膚襯願壓鏇壓醖願簾) = 齋遞鑰餘構繭夢襯壓鬱 範顧憲鬱觸窪鹽壓鬱淵 (衊壓願夢願衊夢夢製襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用